Myriam Labopin

2 months ago | nature.com | Jaime Sanz |Myriam Labopin |Jurjen Versluis |Didier Blaise |Lorenzo Lazzari |Juan Montoro | +7 more

AbstractWe retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy).

Sep 1, 2024 | onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Myriam Labopin |Sorbonne Paris France

CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Pfizer, Celgene, Abbvie, Novartis, and Sanofi. JV has received speaker honoraria from AbbVie and ExCellThera. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, , , et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: long-term follow up of a phase III study. Am J Hematol. 2020; 95: 749-758.

Aug 1, 2024 | nature.com | Myriam Labopin |Depei Wu |Mahmoud Aljurf |Edouard Forcade |Jakob Passweg |Thomas Pabst | +7 more

AbstractCore-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse.

Apr 7, 2024 | acsjournals.onlinelibrary.wiley.com | Justin Loke |Myriam Labopin |Charles Craddock |Gerard Socie

INTRODUCTION Allogeneic stem cell transplantation (SCT) plays a critical role in the management of acute myeloid leukemia (AML) in reducing the risk of disease relapse through cytotoxicity from the conditioning regimen, as well as through the graft-versus-leukemia (GVL) effect.1-3 To ensure time for this to develop, transplant strategies are premised on allografting patients in complete remission (CR).

Dec 12, 2023 | nature.com | Xavier Poiré |Myriam Labopin |Gerard Socie |Edouard Forcade |Yves Chalandon |Mahmoud Aljurf | +3 more

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML.